Jee Hyun Ahn

Seoul National University Hospital

H指数:5

被引数:133

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Subtype-Specific Risk and Temporal Dynamics of Brain Metastases in Metastatic Breast Cancer

乳腺癌脑转移的亚型特异性风险与时间动态特征

Clinical Breast Cancer

IF2.5

2026-03-180

PRE

Prospective Single-Arm Study of Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node-Positive Early Breast Cancer Patients With Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25)

前瞻性单臂研究：对低基因组风险、绝经前淋巴结阳性早期乳腺癌患者使用抑制卵巢功能的治疗内分泌疗法（INTERSTELLAR试验，KBCSG-25）

Journal of Breast Cancer

IF0

2026-02-010

Correction: Lee et al. Discrepancies Between the Tennessee Nomogram and Oncotype DX: Implications for the Korean Breast Cancer Population—The BRAIN Study. Cancers 2025, 17, 3083

更正：Lee等人. 田纳西州列线图与Oncotype DX之间的差异：对韩国乳腺癌人群的启示——BRAIN研究。Cancers 2025, 17, 3083

Cancers

IF4.4

2025-12-310

OAAI

A Randomized Trial of Sentinel Node Biopsy Omission After Neoadjuvant Systemic Therapy in Clinically Node-Negative or Selected Node-Positive Breast Cancer

一项关于新辅助系统性治疗后临床淋巴结阴性或选择性淋巴结阳性乳腺癌中哨兵淋巴结活检省略的随机试验

Journal of Breast Cancer

IF0

2025-12-010

Clinical Usefulness of a Multigene Testing in Patients with Special Histologic Type Breast Cancer

多基因检测在特殊组织学类型乳腺癌患者中的临床应用价值

YONSEI MEDICAL JOURNAL

IF2.8

2025-10-010

PRE

Discrepancies Between the Tennessee Nomogram and Oncotype DX: Implications for the Korean Breast Cancer Population—The BRAIN Study

田纳西列线图与Oncotype DX之间的差异：对韩国乳腺癌人群的启示——BRAIN研究

Cancers 2025, Vol. 17, Page 3083

IF0

2025-09-230

OAAI

Long-term survival outcomes of male breast cancer: the propensity score matching analysis of nationwide registry database

男性乳腺癌的长期生存结局：全国注册登记数据库的倾向性评分匹配分析

breast

IF0

2025-08-060

OAAI

Clinical treatment score post-5 years and survival benefit from extended endocrine therapy for breast cancer patients under and over 50 years of age

BREAST CANCER RESEARCH AND TREATMENT

IF3

2025-03-010

OAAI

Association between Histologic Variants and the Results of Multigene Testing in Patients with Hormone Receptorpositive, HER2-negative Invasive Lobular Cancer

CANCER RESEARCH

IF16.6

2024-05-020

PRE

Prognostic value of multigene test to the patients with Hormone receptorpositive, HER2-negative breast cancer based on special histologic subtypes

CANCER RESEARCH

IF16.6

2024-05-020

PRE

Lymphovascular invasion is an independent prognostic factor in breast cancer irrespective of axillary node metastasis and molecular subtypes

FRONTIERS IN ONCOLOGY

IF3.3

2023-11-176

OAAI

Distinct Prognosis of Minimal Residual Disease According to Breast Cancer Subtype in Patients with Breast or Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy

新辅助化疗后乳腺或淋巴结病理完全缓解患者根据乳腺癌亚型的最小残留病的不同预后

ANNALS OF SURGICAL ONCOLOGY

IF3.5

2023-08-031

PRE

The clinical impact of preoperatively needle-aspiration biopsy for axillary lymph nodes in T1-T2 breast cancer patients with axillary lymph node metastasis

CANCER RESEARCH

IF16.6

2023-03-010

PRE

Frozen Sections in Decision-Making Regarding the Axillary Procedures in Breast Conserving Surgery for Intraductal Carcinoma at Preoperative Diagnosis

JOURNAL OF KOREAN MEDICAL SCIENCE

IF2.3

2023-01-010

OAAI

Early experience of robotic axillary lymph node dissection in patients with node-positive breast cancer

BREAST CANCER RESEARCH AND TREATMENT

IF3

2022-11-239

Clinical treatment score post-5 years (CTS5) and the prediction of survival benefit from extended endocrine therapy for breast cancer patients under and over 50 years of age

CANCER RESEARCH

IF16.6

2022-02-150

PRE

The prognostic significance of Ki67 and progesterone receptor; could they really have prognostic importance in early breast cancer with estrogen receptor positive, HER-2 negative?

CANCER RESEARCH

IF16.6

2022-02-151

PRE

Distinctive clinicopathological features of premenopausal women with intermediate 21-gene recurrence score

CANCER RESEARCH

IF16.6

2022-02-150

PRE

Long-term prognosis of minimal residual disease in breast cancer patients with breast or nodal pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC)

CANCER RESEARCH

IF16.6

2022-02-150

PRE

Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?

Ki-67和乳腺癌预后: 使用术前活检或术后标本检查Ki-67水平是否重要？

BREAST CANCER RESEARCH AND TREATMENT

IF3

2022-01-1317

OAAI

Jee Hyun Ahn

个人简介

教育背景

工作经历

荣誉奖项

研究方向